Ipsen SA, based in France, is a top pharmaceutical company focusing on oncology, neuroscience, and rare diseases. With a history dating back to 1929, Ipsen has evolved from consumer healthcare to specialty care, with a diverse portfolio of medicines. The company recently divested its consumer healthcare business to sharpen its focus on specialty care. Ipsen operates globally, selling over 25 drugs in numerous countries. With a ESG risk rating score of 25.4, Ipsen is deemed a medium-risk investment.